Polish research projects concerning therapeutic potential of SEL24 in Hodgkin lymphoma

15 July 2017
2019_biotech_test_vial_discovery_big

Selvita (WSE: SLV), a leading Poland-based biotechnology firm, and the country’s Institute of Hematology and Transfusion Medicine have published results of a research projects concerning therapeutic potential of SEL24 in Hodgkin Lymphoma.

The article, titled “Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Hodgkin Lymphoma,” was published online in the Blood, on July 11, 2017.

SEL24 is a Selvita-developed first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile, currently investigated for the treatment of patients with relapsed/refractory (R/R) AML. The program entered Phase I/II in early 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology